Tag: #pfizer

Articles related to pfizer

markets

Pfizer Raises 2026 Guidance After Stronger Third Quarter, Names New CFO

Pfizer raised its 2026 revenue and EPS outlook after stronger Q3 results led by non‑COVID drugs; Paxlovid and Comirnaty sales fell while new CFO was named.

$PFE, #pfizer, #pharma, #earnings, #biotech

health

Pfizer says ELREXFIO improved progression-free survival in Phase 3 trial; results are interim

Pfizer reports interim Phase 3 results showing ELREXFIO improved progression-free survival in earlier-line multiple myeloma; safety and overall survival under review.

$PFE, #pfizer, #elrexfio, #elranatamab, #multiplemyeloma, #clinicaltrials

health

FDA Expands Approval of Talzenna Plus Xtandi for HRR‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

FDA on Oct. 26 approved Talzenna plus Xtandi for HRR‑mutated metastatic castration‑sensitive prostate cancer; genetic testing required.

$PFE, #fda, #prostatecancer, #oncology, #pfizer

health

Pfizer’s 25‑valent infant pneumococcal vaccine showed immune responses to all 25 serotypes in Phase 2, company reports

Pfizer's 25‑valent infant pneumococcal vaccine elicited immune responses to all 25 serotypes in Phase 2, with safety similar to Prevnar 20 and stronger serotype 3 responses.

$PFE, #vaccine, #pneumococcal, #pfizer, #pediatrics

health

FDA OKs Pfizer’s TUKYSA for Front‑line Maintenance in HER2‑Positive Metastatic Breast Cancer

FDA expands Pfizer's TUKYSA for front‑line maintenance in unresectable/metastatic HER2‑positive breast cancer; PFS improved 8.6 months, liver risks noted.

$PFE, #her2, #breastcancer, #pfizer, #fda

industry

Pfizer Raises 2026 Revenue Midpoint as Non-COVID Drugs Offset Pandemic Drag

Pfizer lifted the midpoint of its 2026 revenue forecast after stronger-than-expected sales from non-COVID drugs, despite a GAAP loss from write-downs.

$PFE, #pfizer, #pharmaceuticals, #earnings, #covid

health

Pfizer says Phase 3 LITFULO trials met key vitiligo endpoints; plans global regulatory filings

Pfizer said Phase 3 trials of LITFULO (ritlecitinib) met key endpoints in nonsegmental vitiligo across 2,174 patients, and it plans global regulatory filings.

$PFE, #pfizer, #vitiligo, #ritlecitinib

health

EU Authorizes Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for Ages 6 Months and Up

EU clears Pfizer and BioNTech’s 2026–27 XFG-adapted COVID-19 vaccine for people 6 months and older ahead of the 2026–27 respiratory season.

#covid19, #vaccine, #pfizer, #biontech, #xfg

health

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

health

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi

markets

Pfizer Keeps 2026 Outlook as Q1 Revenue Rises 5%; COVID Sales Slide

Pfizer posted 5% revenue growth in Q1 and kept its 2026 outlook, as gains from newer drugs offset steep declines in Comirnaty and Paxlovid sales.

$PFE, #pfizer, #earnings, #pharma